00833nam2-22003131i-450-99000044618040332120001010000044618FED01000044618(Aleph)000044618FED0100004461820001010d--------km-y0itay50------baitay-------001yy1.: Catalogo Generale 1969 453 p.SalernoBernasconi1969v.ill.31 cm0010000415852001Catalogo generaleCataloghi659.13BERNASCONI & C. S.p.A.338941ITUNINARICAUNIMARCBK990000446180403321000044618000001DINEDDINED1.: Catalogo Generale 1969 453 p333861UNINAING0102295nam 2200577 a 450 991079006790332120200520144314.01-61728-480-7(CKB)2670000000090500(EBL)3020935(SSID)ssj0000470344(PQKBManifestationID)11312432(PQKBTitleCode)TC0000470344(PQKBWorkID)10411156(PQKB)11213554(MiAaPQ)EBC3020935(Au-PeEL)EBL3020935(CaPaEBR)ebr10681073(OCoLC)923664583(EXLCZ)99267000000009050020100616d2010 uy 0engur|n|---|||||txtccrInsulin resistance and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH)[electronic resource] /Masato Yoneda ... [et al.]New York Nova Biomedical Booksc20101 online resource (64 p.)Metabolic diseases--laboratory and clinical researchNovinkaDescription based upon print version of record.1-61668-927-7 Includes bibliographical references and index.NAFLD and insulin resistance (IR) -- Pathophysiology of NASH : insulin resistance, free fatty acids, and cytokines -- Adiponectin and NASH -- TNF-[alpha] and NAFLD/NASH -- Leptin and NAFLD/NASH -- Peroxisome proliferators-activated receptors (PPARs) and NAFLD/NASH -- Iron overload and NAFLD/NASH -- Mitochondrial abnormalities and NAFLD/NASH -- Genetic influences in NAFLD/NASH -- Therapeutic strategy for NASH patients -- Natural history of NAFLD -- Conclusions.Metabolic diseases--laboratory and clinical research series.Novinka (Series)Fatty liverInsulin resistanceFatty liver.Insulin resistance.616.3/62Yoneda Masato1486012Yoneda Masato1486012MiAaPQMiAaPQMiAaPQBOOK9910790067903321Insulin resistance and nonalcoholic fatty liver disease (NAFLD)3705365UNINA